Tissue-specific tumor microenvironments influence responses to immunotherapies

AJ Oliver; AS Davey; SP Keam; S Mardiana; JD Chan; B von Scheidt; PA Beavis; IG House; JRM Van Audernaerde; PK Darcy; MH Kershaw; CY Slaney

Journal article

Tissue-specific tumor microenvironments influence responses to immunotherapies

AJ Oliver, AS Davey, SP Keam, S Mardiana, JD Chan, B von Scheidt, PA Beavis, IG House, JRM Van Audernaerde, PK Darcy, MH Kershaw, CY Slaney

Clinical and Translational Immunology | Published : 2019

DOI: 10.1002/cti2.1094

Open access

Download PDF

Abstract

Objectives: Investigation of variable response rates to cancer immunotherapies has exposed the immunosuppressive tumor microenvironment (TME) as a limiting factor of therapeutic efficacy. A determinant of TME composition is the tumor location, and clinical data have revealed associations between certain metastatic sites and reduced responses. Preclinical models to study tissue-specific TMEs have eliminated genetic heterogeneity, but have investigated models with limited clinical relevance. Methods: We investigated the TMEs of tumors at clinically relevant sites of metastasis (liver and lungs) and their impact on αPD-1/αCTLA4 and trimAb (αDR5, α4-1BB, αCD40) therapy responses in the 67NR mous..

View full abstract

University of Melbourne Researchers

Paul Beavis Author

Phillip Darcy Author

Clare Slaney Author

Related Projects (6)

IMMUNOBIOLOGY AND IMMUNOTHERAPY OF CANCER

For 60 years, we have had only 3 effective cancer treatments: surgery, radiation and chemotherapy, often used in combination.The last 5 year..

TARGETING THE TUMOUR MICROENVIRONMENT TO ENHANCE IMMUNOTHERAPY AGAINST CANCER

TARGETING BREAST CANCER USING ADOPTIVE CELL TRANSFER INCORPORATING VACCINATION

Chimeric antigen receptor (CAR) T cell therapy is a novel form of adoptive cellular therapy and has recently generated remarkable effects in..

TARGETING ADENOSINE MEDIATED IMMUNOSUPPRESSION TO ENHANCE CAR T CELL ACTIVITY IN BREAST CANCER

BREAST CANCER THERAPY USING DUAL-SPECIFIC T CELLS

USING LESSONS FROM TOXIC SHOCK SYNDROME TO ENHANCE BREAST CANCER IMMUNOTHERAPY

Grants

Awarded by Cancer Council Victoria

Funding Acknowledgements

This work was supported by grants from Cancer Australia (1100199), the Peter MacCallum Cancer Center Foundation, the National Health and Medical Research Council (NHMRC) of Australia (program grant number 1132373), the National Breast Cancer Foundation (NBCF) of Australia (IIRS-18-064) and Susan G Komen Breast Cancer Foundation (16376637). AJO was supported by an Australian Postgraduate Award. PKD and MHK were supported by NHMRC Senior Research Fellowships. CYS and PAB were supported by a postdoctoral fellowship from the NBCF. SPK was supported by a Cancer Council Victoria Grant-in-aid. JRMVA is a Research fellow of the Research Foundation Flanders (1S32316N).